Cita APA

Fujiwara, Y., Kuchiba, A., Koyama, T., Machida, R., Shimomura, A., Kitano, S., . . . Yamamoto, N. (2020). Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. ESMO Open.

Citación estilo Chicago

Fujiwara, Yutaka, Aya Kuchiba, Takafumi Koyama, Ryunosuke Machida, Akihiko Shimomura, Shigehisa Kitano, Toshio Shimizu, y Noboru Yamamoto. "Infection Risk With PI3K-AKT-mTOR Pathway Inhibitors and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumours in Phase I Clinical Trials." ESMO Open 2020.

Cita MLA

Fujiwara, Yutaka, et al. "Infection Risk With PI3K-AKT-mTOR Pathway Inhibitors and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumours in Phase I Clinical Trials." ESMO Open 2020.